-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Initiates Coverage On Aclaris Therapeutics with Outperform Rating, Announces Price Target of $8

Benzinga·05/28/2025 11:30:34
Listen to the news
Wedbush analyst Martin Fan initiates coverage on Aclaris Therapeutics (NASDAQ:ACRS) with a Outperform rating and announces Price Target of $8.